2023
Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials
de Mesquita Y, Pera Calvi I, Reis Marques I, Almeida Cruz S, Padrao E, Carvalho P, da Silva C, Cardoso R, Moura F, Rafalskiy V. Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials. International Journal Of Obesity 2023, 47: 883-892. PMID: 37460681, DOI: 10.1038/s41366-023-01337-x.Peer-Reviewed Original ResearchConceptsMean differenceRandomized controlled trialsOdds ratioGlucagon-like peptide-1 receptor agonistsMeta-analysis of randomized controlled trialsPeptide-1 receptor agonistsControlled trialsMeta-analysisCo-primary endpointsMethodsWe searched PubMedType 2 diabetesAgonist tirzepatideRisk of biasReview Manager 5.4.1Receptor agonistsReduced BMITherapeutic optionsWaist circumferenceAdverse eventsTirzepatideGastrointestinal symptomsPooled analysisGLP-1PlaceboWeight management1704-P: Efficacy and Safety of Tirzepatide for Weight Loss—A Meta-analysis of Randomized Controlled Trials
MESQUITA Y, CALVI I, MARQUES I, CRUZ S, PADRAO E, CARDOSO R, MOURA F, RAFALSKIY V. 1704-P: Efficacy and Safety of Tirzepatide for Weight Loss—A Meta-analysis of Randomized Controlled Trials. Diabetes 2023, 72 DOI: 10.2337/db23-1704-p.Peer-Reviewed Original ResearchMean differenceDual glucose-dependent insulinotropic polypeptideOdds ratioGlucagon-like peptide-1 receptor agonistsMeta-analysis of randomized controlled trialsPeptide-1 receptor agonistsSafety of tirzepatideGlucose-dependent insulinotropic polypeptideCo-primary endpointsGastrointestinal side effectsWeight lossType 2 diabetesRandomized controlled trialsReceptor agonistsBody weight changesTherapeutic optionsAdverse eventsTirzepatidePooled analysisSide effectsPlaceboWeight managementControlled trialsMeta-analysisBody weight
2022
Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials
Moura F, Wiviott S, Chertow G, Dwyer J, Gause-Nilsson I, Johansson P, Langkilde A, McMurray J, Mosenzon O, Raz I, Rossing P, Wheeler D, Sabatine M, Heerspink H. Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials. European Heart Journal 2022, 43: ehac544.2407. DOI: 10.1093/eurheartj/ehac544.2407.Peer-Reviewed Original ResearchUrinary albumin:creatinine ratioEffects of dapagliflozinSodium-glucose co-transporter 2Kidney eventsType 2 diabetes mellitusDAPA-CKD trialKidney endpointsBaseline eGFRAbsolute rate differenceDAPA-CKDKidney functionHigh urinary albumin:creatinine ratioPatient yearsPooled analysisPatients type 2 diabetes mellitusCardiovascular deathSubgroups of baseline eGFRPatient-level pooled analysisAlbumin:creatinine ratioLevel of kidney functionFollow-up timeCategories of eGFRBaseline kidney functionHigh cardiovascular riskAbsolute risk reduction